Thinking of joining a study?

Register your interest

Become a volunteer?

NCT05361954 | Not yet recruiting | Cancer

Study to Assess the Safety and Preliminary Efficacy of STI-1386 Oncolytic Virus in Relapsed or Refractory Solid Tumors
Sponsor:

Sorrento Therapeutics, Inc.

Brief Summary:

This is a Phase 1b study to assess the safety and tolerability of STI-1386, an oncolytic virus, in subjects with relapsed and refractory solid tumors (RRSTs).

Condition or disease

Cancer

Cancer of Pancreas

Sarcoma

Hepatic Metastasis

Solid Tumor

Intervention/treatment

STI-1386

Phase

Phase 1

Detailed Description:

This is a Phase 1b, dose-ascending study to assess the safety, tolerability and recommended phase 2 dose (RP2D) of STI-1386 in subjects with relapsed and refractory solid tumors (RRSTs). STI-1386 is a second generation oncolytic virus. This is a two-stage study, the first stage uses a single ascending dose, followed by the multiple ascending dose stage.}}

Study Type : Interventional
Estimated Enrollment : 36 participants
Masking : None (Open Label)
Primary Purpose : Treatment
Official Title : A Phase 1b, Dose-Escalation Study of the Safety and Preliminary Efficacy of STI-1386 Oncolytic Virus in Patients With Relapsed or Refractory Solid Tumors
Actual Study Start Date : August 2023
Estimated Primary Completion Date : October 2026
Estimated Study Completion Date : February 2027
Arm Intervention/treatment

Experimental: STI-1386

A dose-escalation standard 3+3 design will be utilized and a total of 3 dosing cohorts are planned, receiving up to 4 mL of 1 x 10^6 / 1 mL, 1 x 10^7 / 1 mL, or 1 x 10^8 / 1 mL.

Friend: STI-1386
Ages Eligible for Study: 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Criteria
Inclusion Criteria
  • Histologically confirmed extracranial solid tumors that are relapsing or refractory including locally advanced pancreatic cancer, unresectable soft tissue sarcomas, hepatic metastases due to colorectal cancer
  • At least one measurable disease per Response Evaluation Criteria in Solid Tumors v. 1.1 (RECIST 1.1) with a non-nodal lesion with longest diameter ≥ 10 mm or nodal lesions with short diameter ≥ 15 mm
  • Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 2
  • As assessed by the investigator, ≥ 3 month life expectancy
  • Adequate hematologic, liver and renal function at Screening as determined by lab criteria
  • Recovered < Grade 2 from all acute toxicities from previous therapy
  • Has not had prior treatment with high dose corticosteroids within the 2 weeks of screening
  • Is willing and able to comply with the study schedule and other protocol requirements
  • Willing to follow contraception guidelines
Exclusion Criteria
  • Have a primary brain tumor
  • Use of an investigational drug or local therapy or agent within 2 weeks of first dose of study drug. Current systemic chemotherapy per investigator's discretion is allowed, but no immune checkpoint inhibitors or immune modulators
  • Use of anticoagulants or anti-platelet agents unless subject can safely start/stop to allow intratumoral injections
  • Use of bevacizumab (Avastin) within 28 days of the STI-1386 injection
  • Diagnosis of other malignancies that have required therapy in the last year or are not in complete remission. Exceptions include non-metastatic basal cell or squamous cell carcinomas of the skin, prostate cancer or cancer in situ that does not require treatment currently or is otherwise under control
  • Requiring chronic systemic immunosuppressants, including steroids > 20 mg/day
  • Presence of bulky disease defined as any single mass > 5 cm in greatest dimension will trigger a discussion to determine eligibility
  • New York Heart Association (NYHA) Class >3 of left ventricular ejection fraction (LVEF) < 50%
  • Prolonged corrected QT interval as determined by 12-lead electrocardiogram
  • Has spinal cord compression or clinically unstable brain metastases within 4 weeks of first dose of study drug
  • Evidence of active herpes infection and/or chronic herpes infection requiring prophylactic antiviral medication that may not be discontinued
  • Has an active or recent COVID-19 infection, must have a negative RT-PCR test and not have had symptoms within 4 weeks of day 1 of study drug administration
  • Any active infection requiring systemic therapy within 72 hours of injection of STI-1386, excluding anti-viral maintenance therapy for HIV
  • Moderate to severe chronic obstructive pulmonary disease or other moderate to severe chronic respiratory conditions unless under treatment and stable for the 3 months of screening
  • Have active human immunodeficiency virus (HIV) infection, human T-cell leukemia virus type 1 (HTLV1) infection, or hepatitis B virus (HBV) or hepatitis C virus (HCV) viremia
  • Pregnant or lactating or up to 3 months post last dose
  • Underlying medical conditions that, in the opinion of the investigator and/or medical monitor will prevent the subject from participating
  • Allergy to acyclovir and related anti-HSV antiviral agents
Study to Assess the Safety and Preliminary Efficacy of STI-1386 Oncolytic Virus in Relapsed or Refractory Solid Tumors

Location Details

Please Choose a site

Study to Assess the Safety and Preliminary Efficacy of STI-1386 Oncolytic Virus in Relapsed or Refractory Solid Tumors

How to Participate

Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.

Locations